Logos Global Management LP Ascendis Pharma A/S Transaction History

Logos Global Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$104.9 - $126.78 $15.7 Million - $19 Million	150,000 New	150,000 $16.1 Million
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $21 Million - $27.6 Million	250,000 New	250,000 $25.8 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $13.7 Million - $20.6 Million	-175,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $17.9 Million - $23.8 Million	175,000 New	175,000 $20.5 Million
Q2 2020 Aug 14, 2020	SELL	$110.87 - $156.01 $13.3 Million - $18.7 Million	-120,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$97.01 - $145.11 $5.81 Million - $8.69 Million	-59,898 Reduced 33.3%	120,000 $13.5 Million
Q4 2019 Feb 14, 2020	BUY	$91.45 - $139.12 $16.5 Million - $25 Million	179,898 New	179,898 $25 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.